Malignant transformation of a hepatocellular adenoma
https://doi.org/10.24835/1607-0763-2019-4-76-85
Abstract
Hepatocellular adenoma (HCA) is the uncommon benign liver tumor, which is characterized by monoclonal proliferation of mature hepatocytes. HCAs have many genetic and molecular features that determine their natural behavior (such as malignant transformation), but MRI features are studied just for two subtypes (H-HCA и I-ICA). This article presents clinical case of 58 y.o. woman with hepatitis C, hepatic adenomatosis and malignant transformation of one of multiple HCAs.
About the Authors
B. M. Medvedeva
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
Dr. of Sci. (Med.), lead researcher, Diagnostic Radiology department of the Research Institute of Clinical and Experimental radiology
D. M. Khaitsman
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
resident of the interventional radiology laboratory of the Research Institute of Clinical and Experimental radiology
115478, Moscow, Kashirskoe shosse, 24
Phone: +7-916-251-55-52
A. B. Lukianchenko
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor, lead researcher, Diagnostic Radiology department of the Research Institute of Clinical and Experimental radiology
E. A. Moroz
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Cand. of Sci. (Med.), senior researcher, Pathology department of N.N.Trapeznikov Research Institute of Clinical oncology
Russian Federation
Cand. of Sci. (Med.), senior researcher, Pathology department of N.N.Trapeznikov Research Institute of Clinical oncology
References
1. Nault J.C., Bioulac-Sage P., Zucman-Rossi J. Hepatocellular benign tumours – from molecular classification to personalized clinical care. Gastroenterology. 2013;144: 888–902. https://doi.org/10.1053/j.gastro.2013.02.032
2. Baum J.K., Bookstein J.J., Holtz F., Klein E.W. Possible association between benign hepatomas and oral contraceptives. Lancet. 1973; 302: 926–929. https://doi.org/10.1016/s0140-6736(73)92594-4
3. Calderaro J., Labrune P., MorcretteG., RebouissouS., FrancoD., Prévot S., Quaglia A., Bedossa P., Libbrecht L., Terracciano,L., Smit G.P., Bioulac-Sage P., Zucman- Rossi J. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J. Hepatol. 2013; 58: 350–357. https://doi.org/10.1016/j.jhep.2012.09.030
4. Bonder A., Afdhal N. Evaluation of liver lesions. Clin. Liver Dis. 2012; 16: 271–283. https://doi.org/10.1016/j.cld.2012.03.001
5. Rooks J.B., Ory H.W., Ishak K.G., Strauss L.T., Greenspan J.R., Hill A.P., Tyler C.W. Jr. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA. 1979; 242 (7): 644–648.
6. Bioulac-Sage P., Laumonier H., Couchy G., Le Bail B., Sa Cunha A., Rullier A., Laurent C., Blanc J.F., Cubel G., Trillaud H., Zucman-Rossi J., Balabaud C., Saric J. Hepatocellular Adenoma Management and Phenotypic Classification: the Bordeaux Experience. Hepatology. 2009; 50 (2): 481–489. https://doi.org/10.1002/hep.22995
7. EASL CPG benignlivertumours. J. Hepatol. 2016; 65: 386–398. https://doi.org/10.1016/j.jhep.2016.04.001
8. Choi W-T., Kakar S. Atypical Hepatocellular Neoplasms: Review of Clinical, Morphologic, Immunohistochemical, Molecular, and Cytogenetic Features. Adv. Anat. Pathol. 2018; 25 (4): 254–262. https://doi.org/10.1097/PAP.0000000000000189
9. Sempoux C., Balabaud C., Bioulac-Sage P. Malignant transformation of hepatocellular adenoma. Hepatic Oncol. 2014; 1: 421–431. https://doi.org/10.2217/hep.14.14
10. Rebouissou S., Franconi A., Calderaro J., Letouzé E., Imbeaud S., Pilati C., Nault J.C., Couchy G., Laurent A., Balabaud C., Bioulac-Sage P., Zucman-Rossi J. Genotypephenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression. Hepatology. 2016; 64 (6): 2047–2061. https://doi.org/10.1002/hep.28638
11. Brant W.E. Brant and Helms’ Fundamentals of Diagnostic Radiology 5ed. Wolters Kluwer; 2007; 2231 p.
12. Braga L., Altun E., Armao D., Semelka RC. Abdominalpelvic MRI. 4ed. Wiley-Blackwell; 2016; Chapter 2, 90: 92–93.
13. Harisinghani M.G., Mueller P.R. Teaching Atlas of Abdominal Imaging. Thieme. 2009; 11,12 p.
14. Laumonier H., Bioulac-Sage P., Laurent C., Zucman- Rossi J., Balabaud C., Trillaud H. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology. 2008; 48: 808–818. https://doi.org/10.1002/hep.22417
15. van Aalten S.M., Thomeer M.G., Terkivatan T., Dwarkasing R.S., Verheij J., de Man R.A., Ijzermans J.N. Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology. 2011; 261: 172–181. https://doi.org/10.1148/radiol.11110023
16. Lukianchenko A.B., Medvedeva B.M. The current approaches to the diagnosis of hepatocellular adenomas (literature review аnd clinical cases). Medical Visualization. 2013; 1: 33–43. (In Russian)
17. Dharmana H., Saravana-Bawan S., Girgis S., Low G. Hepatocellular adenoma: imaging review of the various molecular subtypes. Clin. Radiol. 2017; 72: 276–285. https://doi.org/10.1016/j.crad.2016.12.020
18. Reizine E., Ronot M., Pigneur F., Purcell Y., Mulé S., Dioguardi Burgio M., Calderaro J., Amaddeo G., Laurent A., Vilgrain V., Luciani A. Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping. Eur. Radiol. 2019; 29 (7): 3791–3801. https://doi.org/10.1007/s00330-019-06150-7
19. Sciarra A., Schmidt S., Pellegrinelli A., Maggioni M., Dondossola D., Pasquier J., Cigala C., Tosi D., Halkic N., Bulfamante G., Viale G., Bosari S., Balabaud C., Bioulac- Sage P., Sempoux C. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy. Liver Int. 2019; 39 (1): 158–167. https://doi.org/10.1111/liv.13964
20. Guo Y., Li W., Xie Z., Zhang Y., Fang Y., Cai W., Hong G. Diagnostic Value of Gd-EOB-DTPA-MRI for Hepatocellular Adenoma: A Meta-Analysis. J. Cancer. 2017; 8 (7): 1301–1310. https://doi.org/10.7150/jca.17778
Review
For citations:
Medvedeva B.M., Khaitsman D.M., Lukianchenko A.B., Moroz E.A. Malignant transformation of a hepatocellular adenoma. Medical Visualization. 2019;(4):76-85. (In Russ.) https://doi.org/10.24835/1607-0763-2019-4-76-85
Views:
1413
Email this article 